120
Participants
Start Date
July 23, 2024
Primary Completion Date
October 31, 2028
Study Completion Date
September 30, 2030
Dostarlimab
Anti-PD-1 monoclonal antibody
Chemotherapy
"* mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin."
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Angers
NOT_YET_RECRUITING
Institut du Cancer Avignon-Provence, Avignon
NOT_YET_RECRUITING
CHU Jean Minjoz, Besançon
NOT_YET_RECRUITING
CHU Morvan, Brest
NOT_YET_RECRUITING
Centre François Baclesse, Caen
NOT_YET_RECRUITING
Centre Jean Perrin, Clermont-Ferrand
NOT_YET_RECRUITING
CHU - Henri Mondor, Créteil
NOT_YET_RECRUITING
Centre Georges François Leclerc, Dijon
RECRUITING
Centre Léon Bérard, Lyon
NOT_YET_RECRUITING
Hôpital la Timone, Marseille
NOT_YET_RECRUITING
Institut Paoli Calmettes, Marseille
NOT_YET_RECRUITING
Institut de Cancérologie de Lorraine, Nancy
NOT_YET_RECRUITING
Institut Mutualiste Montsouris, Paris
NOT_YET_RECRUITING
CHU de Bordeaux - Hôpital Haut -Lèvêque, Pessac
NOT_YET_RECRUITING
CHU de Poitiers, Poitiers
NOT_YET_RECRUITING
Institut Jean Godinot, Reims
NOT_YET_RECRUITING
Centre Eugène Marquis, Rennes
NOT_YET_RECRUITING
CHU de Rouen, Rouen
NOT_YET_RECRUITING
Institut de Cancérologie de l'Ouest, Saint-Herblain
NOT_YET_RECRUITING
CHU de Toulouse Hôpital Rangueil, Toulouse
NOT_YET_RECRUITING
Gustave Roussy Grand Paris, Villejuif
NOT_YET_RECRUITING
Hôpital Saint-Antoine, Paris
Collaborators (1)
National Cancer Institute, France
OTHER_GOV
GlaxoSmithKline
INDUSTRY
UNICANCER
OTHER